A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Study Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Teva Identifier
TV53408-IMM-20042
ClinicalTrials.gov Identifier
NCT06807463
Study Status
Not yet recruiting
Trial Condition(s)
Celiac Disease
Interventions
Drug: TEV-53408, Placebo

Study Description

Primary objectives:
- The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.
- The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.

Secondary objective:
- A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.
- The expected trial duration per participant is approximately 86 weeks.

Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 Years to 64 Years
Trial Duration
February 17, 2025 - August 09, 2027
Phase
Phase 2

Study Type

Interventional